Plasma MCP-1 and changes on cognitive function in community-dwelling older adults.
Alzheimers Res Ther
; 14(1): 5, 2022 01 07.
Article
in En
| MEDLINE
| ID: mdl-34996522
ABSTRACT
BACKGROUND:
Monocyte Chemoattractant Protein-1 (MCP-1), a glial-derived chemokine, mediates neuroinflammation and may regulate memory outcomes among older adults. We aimed to explore the associations of plasma MCP-1 levels (alone and in combination with ß-amyloid deposition-Aß42/40) with overall and domain-specific cognitive evolution among older adults.METHODS:
Secondary analyses including 1097 subjects (mean age = 75.3 years ± 4.4; 63.8% women) from the Multidomain Alzheimer Preventive Trial (MAPT). MCP-1 (higher is worse) and Aß42/40 (lower is worse) were measured in plasma collected at year 1. MCP-1 in continuous and as a dichotomy (values in the highest quartile (MCP-1+)) were used, as well as a dichotomy of Aß42/40. Outcomes were measured annually over 4 years and included the following cognitive composite z-score (CCS), the Mini-Mental State Examination (MMSE), and Clinical Dementia Rating (CDR) sum of boxes (overall cognitive function); composite executive function z-score, composite attention z-score, Free and Cued Selective Reminding Test (FCSRT - memory).RESULTS:
Plasma MCP-1 as a continuous variable was associated with the worsening of episodic memory over 4 years of follow-up, specifically in measures of free and cued delayed recall. MCP-1+ was associated with worse evolution in the CCS (4-year between-group difference ß = -0.14, 95%CI = -0.26, -0.02) and the CDR sum of boxes (2-year ß = 0.19, 95%CI = 0.06, 0.32). In domain-specific analyses, MCP-1+ was associated with declines in the FCSRT delayed recall sub-domains. In the presence of low Aß42/40, MCP-1+ was not associated with greater declines in cognitive functions. The interaction with continuous biomarker values Aß42/40× MCP-1 × time was significant in models with CDR sum of boxes and FCSRT DTR as dependent variables.CONCLUSIONS:
Baseline plasma MCP-1 levels were associated with longitudinal declines in overall cognitive and episodic memory performance in older adults over a 4-year follow-up. How plasma MCP-1 interacts with Aß42/40 to determine cognitive decline at different stages of cognitive decline/dementia should be clarified by further research. The MCP-1 association on cognitive decline was strongest in those with amyloid plaques, as measured by blood plasma Aß42/40.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Alzheimer Disease
/
Cognitive Dysfunction
Type of study:
Diagnostic_studies
/
Prognostic_studies
Limits:
Aged
/
Female
/
Humans
/
Male
Language:
En
Journal:
Alzheimers Res Ther
Year:
2022
Type:
Article
Affiliation country:
France